: Diverticular disease is an increasingly common issue, with a variety of clinical presentations and treatment options. However, very few prospective cohort studies explore outcomes between the different presentations and treatments. The Diverticular Disease Registry (DDR Trial) is a multicenter, prospective, observational cohort study on behalf of the Advanced International Mini-Invasive Surgery (AIMS) academy clinical research network. The DDR Trial aims to investigate the short-term postoperative and long-term quality of life outcomes in patients undergoing surgery or medical treatments for diverticular disease. DDR Trial is open to participation by all tertiary-care hospitals. DDR Trial has been registered at ClinicalTrials.gov (NCT 04907383). Data collection will be recorded on Research Electronic Data Capture (REDCap) starting on June 1st, 2021 and will end after 5 years of recruitment. All adult patients with imaging-proven colonic diverticular disease (i.e., symptomatic colonic diverticulosis including diverticular bleeding, diverticulitis, and Symptomatic Uncomplicated Diverticular Disease) will be included. The primary outcome of DDR Trial is quality of life assessment at 12-month according to the Gastrointestinal Quality of Life Index (GIQLI). The secondary outcome is 30-day postoperative outcomes according to the Clavien-Dindo classification. DDR Trial will significantly advance in identifying the optimal care for patients with diverticular disease by exploring outcomes of different presentations and treatments. Highlights:
Background: The management of rectal cancer is multimodal and involves a multidisciplinary team of cancer specialists with expertise in medical oncology, surgical oncology, radiation oncology and radiology. It is crucial for highly specialized centers to collaborate via networks that aim to maintain uniformity in every aspect of treatment and rigorously gather patients’ data, from the first clinical evaluation to the last follow-up visit. The Advanced International Mini-Invasive Surgery (AIMS) academy clinical research network aims to create a rectal cancer registry. This will prospectively collect the data of patients operated on for non-metastatic rectal cancer in high volume colorectal surgical units through a well design pre-fashioned database for non-metastatic rectal cancer, in order to take all multidisciplinary aspects into consideration. Methods/Design: The protocol describes a multicenter prospective observational cohort study, investigating demographics, frailty, cancer-related features, surgical and radiological parameters, and oncological outcomes among patients with non-metastatic rectal cancer who are candidates for surgery with curative intent. Patients enrolled in the present registry will be followed up for 5 years after surgery. Discussion: Standardization and centralization of data collection for neoplastic diseases is a virtuous process for patient care. The creation of a register will allow the control of the quality of treatments provided and permit prospective and retrospective studies to be carried out on complete and reliable high quality data. Establishing data collection in a prospective and systematic fashion is the only possibility to preserve the enormous resource that each patient represents.
Background/Objectives: Frailty is increasingly recognized as a major determinant of postoperative outcomes in older patients undergoing oncologic surgery. The Primary Care Frailty Index (PC-FI), a deficit accumulation-based instrument derived from routinely available clinical information, has recently been proposed as a practical frailty assessment tool. However, evidence supporting its application in gastrointestinal surgical oncology remains limited. Methods: We conducted a retrospective cohort study including patients aged ≥65 years who underwent elective major colorectal or gastric cancer surgery between January 2022 and October 2025 at a tertiary Italian hospital. Patients with a PC-FI > 0.07 were included and categorized as having mild (0.07–0.13) or moderate-to-severe frailty (≥0.14). Postoperative outcomes included the Comprehensive Complication Index (CCI), Clavien–Dindo classification, and length of hospital stay. Receiver operating characteristic (ROC) analysis was performed to compare the discriminative performance of PC-FI, ASA classification, and the ACS Surgical Risk Calculator. Results: Ninety-two patients met the inclusion criteria. Patients with moderate-to-severe frailty were significantly older and had higher ASA class, Charlson Comorbidity Index, and ACS morbidity estimates than mildly frail patients. They also experienced a greater postoperative complication burden (mean CCI 25.96 vs. 16.40, p = 0.02) and longer hospital stay (9.89 vs. 7.43 days, p = 0.01). ROC analysis demonstrated modest discriminative performance for PC-FI (AUC 0.63), comparable to ASA classification (AUC 0.68) and the ACS morbidity score (AUC 0.70), without statistically significant differences among the three instruments. Conclusions: Higher PC-FI scores were associated with increased postoperative morbidity and prolonged recovery following major gastrointestinal oncologic surgery. Although its discriminative performance was modest and does not support its use as a stand-alone risk prediction tool, the PC-FI may represent a simple first-line frailty screening instrument to identify older patients who could benefit from comprehensive multidisciplinary perioperative assessment.